Daniel E. Wolf, P.C. - Partner

PDF Print Friendly Page
Daniel E. Wolf, P.C.

Download V-Card

New York
Phone: +1 212-446-4884
Fax: +1 212-446-4900
Overview News Events Publications

Professional Profile

Daniel Wolf’s practice focuses on mergers and acquisitions where he represents public and private companies, as well as private equity firms, in a variety of domestic and international transactions. His transactional experience spans the range of M&A activity including many significant cross-border and contested transactions. He also counsels public company clients on governance, finance, securities and other general corporate matters.

In the last six consecutive years, Chambers and Partners listed Daniel as a top M&A attorney in Chambers USA. According to Chambers Global, one source noted him as an “exceptional lawyer” and “one of the smartest guys I have ever met.” Daniel has also been listed as a “Leading Lawyer” in The Legal 500 U.S. for M&A - Large Deals ($1BN+) and recognized in the 2017 edition of Who’s Who Legal: M&A and Governance. Daniel is also listed as a New York Super Lawyer by Super Lawyers magazine in 2013–2016 and endorsed by PLC’s Mergers and Acquisitions multi-jurisdictional guide. He was also recognized as as one of the “Top 50: America's M&A Star Dealmakers 2013” by the Global M&A Network.

Representative Matters

Public Company Representations

  • Teva Pharmaceutical in its $40.5 billion acquisition of Allergan Generics and U.S. antitrust clearance, which includes the largest ever drug divestiture in a pharmaceutical merger involving sales to 11 different buyers for an aggregate of approximately $1.7 billion, and its $500 million acquisition of Anda, a drug distribution business

  • Mead Johnson Nutrition in its pending $18 billion sale to Reckitt Benckiser plc

  • Bristol-Myers Squibb in its $4.3 billion sale to AstraZeneca of its interest in the companies' diabetes alliance, $7 billion acquisition of Amylin Pharmaceuticals and joint collaboration with AstraZeneca, $2.5 billion acquisition of Inhibitex and $885 million acquisition of ZymoGenetics

  • Swift Transportation in its $6 billion stock-for-stock merger with Knight Transportation

  • Abbott in its $5.8 billion acquisition of Alere Inc.

  • Cendant Corporation (now Avis Budget Group) in its separation into four companies through the spin-offs of its Realogy and Wyndham Worldwide divisions and the $4.3 billion sale of its Travelport division to the Blackstone Group*

  • Danaher Corporation in the $4 billion acquisition of Cepheid, and in the $650 million acquisition of MDS Analytical Technologies from MDS and in the related $450 million acquisition of a 50% stake in the Applied Biosystems/MDS SCIEX joint venture from Life Technologies Corporation

  • Advance Auto Parts in its $2 billion acquisition of General Parts International

  • Ventas, Inc. in its $1.75 billion acquisition of Ardent Medical Services, Inc.

  • AboveNet Communications in its $1.6 billion merger with Metromedia Fiber Network*

  • Celator Pharmaceuticals in its $1.5 billion sale to Jazz Pharmaceuticals

  • Syncor International Corporation in its $1 billion acquisition by Cardinal Health*

  • Blackstone Group in its $820 million PIPE investment in NCR Corporation

  • Duff & Phelps Corporation in its $665 million acquisition by a private equity consortium led by The Carlyle Group

  • Avis Budget Group in its $500 million acquisition of Zipcar

  • Horizon Lines, a Jones Act shipper, in the cross-conditioned sale of its Hawaii business to Pasha International and sale of the company to Matson, with a combined enterprise value of approximately $600 million

  • Knight Capital Group in numerous acquisitions and dispositions in its global markets and asset management divisions

Cross-Border Transactions

  • BHP Billiton in its approximately $150 billion withdrawn acquisition of Rio Tinto*

  • Misys Limited, a UK-based portfolio company of Vista Equity Partners, in its $4.8 billion take-private and combination with Canada-based financial technology firm DH Corporation

  • ABB Ltd, the Swiss conglomerate, in its $4.2 billion acquisition of Baldor Electric Company and $3.9 billion acquisition of Thomas & Betts Corporation

  • Tronox Incorporated in its $3.4 billion acquisition of the South African and Australian mineral sands business of Exxaro Resources Ltd. of South Africa

  • ECI Telecom Ltd. in its $1.2 billion buyout by a private equity consortium in the first significant private equity buyout of an Israeli public company*

  • Avis Budget Group in its $1 billion acquisition of Avis Europe plc

  • Given Imaging Ltd. of Israel in its $1 billion sale to Covidien plc

  • Danaher Corporation in its $685 million sale of its Pacific Scientific Aerospace business to Meggitt PLC

  • Acorda Therapeutics in its $363 million acquisition of Finnish company Biotie Therapies

  • Teva Pharmaceutical in its Japanese joint venture with Takeda Pharmaceutical relating to the sale of generic medicines in Japan

  • Bristol-Myers Squibb in its collaboration arrangement with Reckitt Benckiser for distribution and future acquisition of several of BMS' over-the-counter medicines sold primarily in Brazil and Mexico

Contested Situations

  • Baxalta in connection with Shire plc’s unsolicited takeover bid resulting in a $32 billion stock-and-cash sale

  • Blackstone Group in its approximately $26 billion acquisition proposal for Dell

  • American General Corporation in its $25 billion merger-of-equals transaction with Prudential plc and subsequent hostile takeover by American International Group (AIG)*

  • Avis Budget Group in its unsolicited $1.5 billion offer to acquire Dollar Thrifty Automotive Group

  • Prestige Brands in connection with Genomma Lab's unsolicited $834 million acquisition proposal and potential proxy contest

  • Advance Auto Parts in its agreement with activist hedge fund Starboard Value relating to board composition and leadership changes

  • The Vitamin Shoppe in its agreement with activist hedge fund Carlson Capital relating to board composition

  • Avis Budget Group in its agreement with hedge fund SRS Investment Management relating to board composition

Private Equity Sponsor Transactions

  • Blackstone Group in its $6.1 billion acquisition of TeamHealth and in its acquisition, along with Goldman Sachs Merchant Banking, of Ipreo from KKR

  • Vista Equity Partners in multiple take-privates including its $1.65 billion acquisition of Cvent, $1.0 billion acquisition of Websense, $644 million acquisition of Greenway Medical Technologies and $178 million acquisition of XRS

  • Och-Ziff Real Estate and Norge Churchill in the approximately $800 million announced leveraged buyout of Winston Hotels, Inc., a public hotel REIT*

  • Golden Gate Capital in its $470 million acquisition of California Pizza Kitchen

  • Leonard Green & Partners in its leveraged buyout of Twinlab Corporation and subsequent high-yield debt, and initial and secondary equity public offerings*

  • Fox Paine & Company, a leading private equity firm, and many of its portfolio companies in numerous M&A and finance transactions*

Private Company Transactions

  • Bristol-Myers Squibb in its up to $3 billion divestiture of its HIV pipeline to ViiV Healthcare, $2.1 billion acquisition of Cardioxyl Pharmaceuticals, Inc., $1.25 billion acquisition of Flexus Biosciences, Inc., $1.25 billion acquisition of Promedior, Inc., $725 million acquisition of iPierian, $520 million acquisition of Cormorant Pharmaceuticals, $475 million acquisition of F-star Alpha Ltd., and $444 million acquisition of Galecto Biotech AB, in each case including milestones

  • Websense, a Vista Equity Partners portfolio company, in its $1.9 billion sale to Raytheon

  • Blackstone Group in its equity investment, along with GIC, of $750 million in Kronos

  • Gerson Lehrman Group in the investment by Silver Lake of approximately $200 million* and the investment by SFW Capital of $212 million

  • Dresdner Bank in its acquisition of the investment banking business of Wasserstein Perella Group, Inc.*


Daniel is a leading contributing author of the Kirkland M&A Update. Daniel’s thought leadership has been recognized by various academic and business publications, including The Wall Street Journal, The Harvard Law School Forum on Corporate Governance and Financial Regulation, The New York Times’ Deal Professor, Investment Dealers’ Digest, Deal Lawyers, Practical Law Company (PLC) and Law360.
© 2017 Kirkland & Ellis LLP